Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
32942039
DOI
10.1016/j.autrev.2020.102671
PII: S1568-9972(20)30246-9
Knihovny.cz E-zdroje
- Klíčová slova
- Focal segmental glomerulosclerosis, Infections, Long-term remission, Minimal change disease, Nephrotic syndrome, Rituximab,
- MeSH
- dospělí MeSH
- fokálně segmentální glomeruloskleróza * farmakoterapie MeSH
- imunologické faktory terapeutické užití MeSH
- imunosupresiva škodlivé účinky MeSH
- lidé MeSH
- lipoidní nefróza * farmakoterapie MeSH
- nefrotický syndrom MeSH
- recidiva MeSH
- rituximab terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- imunologické faktory MeSH
- imunosupresiva MeSH
- rituximab MeSH
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations.
Department of Nephrology and Transplantation University Hospital of Wales Cardiff UK
Department of Nephrology Juntendo University Faculty of Medicine Tokyo Japan
Department of Nephrology Radboud University Medical Center PO Box 9101 6500 HB Nijmegen Netherlands
Department of Nephrology University of Brescia Hospital of Montichiari Brescia Italy
Division of Nephrology and Hypertension Mayo Clinic Rochester MN USA
Division of Nephrology Columbia University Medical Center NY New York USA
Nephrology Post Graduate Institute of Medical Education and Research Chandigarh India
Tareev Clinic of Internal Diseases Sechenov 1st Moscow State Medical University Moscow Russia
University College London Department of Renal Medicine Royal Free Hospital London UK
Citace poskytuje Crossref.org